Williams Jones & Associates LLC boosted its position in shares of Merck & Co. (NYSE:MRK) by 91.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 131,748 shares of the company’s stock after buying an additional 63,079 shares during the period. Williams Jones & Associates LLC’s holdings in Merck & Co. were worth $7,590,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of MRK. QCI Asset Management Inc. NY raised its stake in Merck & Co. by 1.1% in the second quarter. QCI Asset Management Inc. NY now owns 2,382 shares of the company’s stock worth $137,000 after buying an additional 27 shares during the period. Annex Advisory Services LLC raised its stake in Merck & Co. by 0.4% in the second quarter. Annex Advisory Services LLC now owns 12,081 shares of the company’s stock worth $696,000 after buying an additional 43 shares during the period. Landmark Financial Advisors LLC raised its stake in Merck & Co. by 0.7% in the second quarter. Landmark Financial Advisors LLC now owns 6,393 shares of the company’s stock worth $368,000 after buying an additional 43 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in Merck & Co. by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 5,234 shares of the company’s stock worth $302,000 after buying an additional 44 shares during the period. Finally, Cornerstone Advisors Inc. raised its stake in Merck & Co. by 0.9% in the second quarter. Cornerstone Advisors Inc. now owns 4,849 shares of the company’s stock worth $279,000 after buying an additional 45 shares during the period. 73.24% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Shares of Merck & Co. (NYSE:MRK) traded down 1.32% on Friday, reaching $61.87. The company had a trading volume of 7,696,863 shares. The company’s 50-day moving average price is $61.69 and its 200-day moving average price is $59.50. The firm has a market capitalization of $170.58 billion, a price-to-earnings ratio of 31.60 and a beta of 0.76. Merck & Co. has a 52-week low of $47.97 and a 52-week high of $65.46.

Merck & Co. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, October 25th. The company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. Merck & Co. had a return on equity of 24.25% and a net margin of 13.76%. The company had revenue of $10.50 billion for the quarter, compared to analysts’ expectations of $10.17 billion. During the same quarter in the prior year, the business posted $0.96 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. On average, analysts predict that Merck & Co. will post $3.77 earnings per share for the current year.

A number of research firms have recently issued reports on MRK. Vetr lowered shares of Merck & Co. from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research lowered shares of Merck & Co. from a “buy” rating to a “hold” rating in a research report on Friday. Argus reissued a “buy” rating and issued a $80.00 price target (up from $65.00) on shares of Merck & Co. in a research report on Thursday, October 27th. Finally, Jefferies Group reissued a “hold” rating and issued a $65.00 price target on shares of Merck & Co. in a research report on Sunday, October 16th. Thirteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of €66.53 ($71.54).

In other news, Director Rochelle B. Lazarus sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of €59.06 ($63.51), for a total transaction of €1,181,200.00 ($1,270,107.53). Following the sale, the director now owns 9,594 shares in the company, valued at approximately €566,621.64 ($609,270.58). The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of €62.07 ($66.74), for a total value of €2,532,456.00 ($2,723,070.97). Following the sale, the insider now owns 128,973 shares in the company, valued at approximately €8,005,354.11 ($8,607,907.65). The disclosure for this sale can be found here. Insiders own 0.05% of the company’s stock.

About Merck & Co.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Receive News & Stock Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related stocks with our FREE daily email newsletter.